Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
2.980
+0.130 (4.56%)
At close: Mar 9, 2026, 4:00 PM EDT
2.980
0.00 (0.00%)
After-hours: Mar 9, 2026, 5:04 PM EDT
Anixa Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
99.47M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionANIX News
- 11 hours ago - Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology - PRNewsWire
- 7 days ago - Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress - PRNewsWire
- 14 days ago - Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat - PRNewsWire
- 4 weeks ago - Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation - PRNewsWire
- 4 weeks ago - EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues - Benzinga
- 5 weeks ago - Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization - PRNewsWire
- 5 weeks ago - Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology - PRNewsWire
- 6 weeks ago - Water Tower Research Publishes Initiation of Coverage Report on Anixa Biosciences, Inc., “Anixa's T-Cell Innovations Show Breakthrough Potential in Solid Tumors” - TheNewswire